Researchers at Children's Hospital of Philadelphia (CHOP) and the Children's Oncology Group (COG) found that larotrectinib, ...

In the Phase II ADVL1823 study, researchers evaluated Vitrakvi in children with newly diagnosed IFS and other solid tumors with NTRK fusions.

Neurotrophic tropomyosin receptor kinase (NTRK) are a family of receptors involved in neural development. An NTRK gene fusion is an alteration that occurs when a piece of the chromosome containing the ...

The EU drugs regulator cleared Vitrakvi (larotrectinib) for the treatment of patients with solid tumours that have an NTRK gene fusion, are locally advanced, metastatic or for whom surgical ...

Augtyro was recommended as monotherapy for the treatment of adult and pediatric patients 12 years of age and older with advanced solid tumors expressing a NTRK gene fusion and (1) have received a ...

It also recommended approval for the treatment of certain adult and pediatric patients aged 12 years and older with advanced solid tumors expressing a NTRK gene fusion, according to a statement.

"Larotrectinib had a manageable safety profile in all patients with TRK fusion primary CNS tumors," said Perreault. "Five ...